[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629552":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":42,"collaborators":24,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":24,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":24,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":24,"overallStatus":64,"whyStopped":24,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence A","EXPERIMENTAL","Period 1 : Reference drug(AD-1181), Period 2 : Test drug(AD-118)\n\nSingle-dose oral administration of AD-1181 in Period 1, followed by single-dose oral administration of AD-118 in Period 2.",[13],"Drug: AD-118, AD-1181",{"label":15,"type":10,"description":16,"interventionNames":17},"Sequence B","Period 1 : Test drug(AD-118), Period 2 : Reference drug(AD-1181)\n\nSingle-dose oral administration of AD-118 in Period 1, followed by single-dose oral administration of AD-1181 in Period 2.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","AD-118, AD-1181","Single-dose oral administration of AD-118 or AD-1181, according to randomized sequence.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"JaeHun Jung","CONTACT","+82-31-891-5683","jhjung@addpharma.co.kr",[32],{"facility":33,"status":24,"city":34,"state":24,"zip":24,"country":35,"countryCode":24,"cosmosGeoPoint":36,"geoPoint":41,"contacts":24},"H PLUS YANGJI HOSPITAL, Seoul","Seoul","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},{"type":43,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100629552","phase-1-a-study-to-evaluate-the-safety-and-pharmacokinetics-of-ad-118-and-ad-1181-in-healthy-adult-subjects-100629552",false,"NCT07476157","A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* Subjects aged 19 years or older and under 65 years at the screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years","64 Years",{"count":56,"type":57},70,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects",[63],"Chronic Heart Failure","NOT_YET_RECRUITING","2026-03-12",{"date":67,"type":68},"2026-03-17","ACTUAL",{"date":70,"type":57},"2026-04",{"date":72,"type":57},"2026-05",{"name":5,"class":6},1]